Physician profile
Paul T Naylor
NPI 1265407878
$183,639.42
in general payments reported to CMS, 2019-2025
12 companies · $509 in 2025
The $509 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $33.42 · 2021: $41K · 2022: $61K · 2023: $79K · 2024: $1,148 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $77K · Food and Beverage: $2,950 · Travel and Lodging: $1,228 · Entertainment: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $76,666.64 |
| Food and Beverage | $2,950.26 |
| Travel and Lodging | $1,227.93 |
| Entertainment | $227.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $182,674.05 | 2021-2025 | Irrisept |
| Alpha Orthopedic Systems | $279.77 | 2019 | |
| Stryker Corporation | $143.20 | 2021 | |
| Zimmer Biomet Holdings, INC. | $121.67 | 2021-2022 | |
| Depuy Synthes Sales INC. | $119.86 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.46 | 2024 | Xifaxan |
| Radius Health, INC. | $78.16 | 2019-2020 | |
| Horizon Therapeutics Plc | $59.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.48 | 2025 | Entyvio |
| Smith+Nephew, INC. | $21.95 | 2019 | |
| Ethicon US, LLC | $17.07 | 2022 | |
| Pacira Therapeutics, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$766,366.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Naylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.